BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34449586)

  • 21. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management impact of
    Meijer D; van Leeuwen PJ; Oosterholt PMJ; Bodar YJL; van der Poel HG; Hendrikse NH; Donswijk ML; Wondergem M; Vellekoop AE; van Moorselaar RJA; Nieuwenhuijzen JA; Oprea-Lager DE; Vis AN
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2960-2969. PubMed ID: 33547552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Prospective Study on
    Rousseau E; Wilson D; Lacroix-Poisson F; Krauze A; Chi K; Gleave M; McKenzie M; Tyldesley S; Goldenberg SL; Bénard F
    J Nucl Med; 2019 Nov; 60(11):1587-1593. PubMed ID: 30979820
    [No Abstract]   [Full Text] [Related]  

  • 25. Prospective comparison of whole-body MRI and
    Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of
    Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
    BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
    Glicksman RM; Metser U; Vines D; Valliant J; Liu Z; Chung PW; Bristow RG; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Green D; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
    Eur Urol; 2021 Sep; 80(3):374-382. PubMed ID: 33685838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
    Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
    Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications.
    Morawitz J; Kirchner J; Lakes J; Bruckmann NM; Mamlins E; Hiester A; Aissa J; Loberg C; Schimmöller L; Arsov C; Antke C; Albers P; Antoch G; Sawicki LM
    Eur J Radiol; 2021 Mar; 136():109556. PubMed ID: 33485127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of PSMA-based
    Mena E; Lindenberg ML; Shih JH; Adler S; Harmon S; Bergvall E; Citrin D; Dahut W; Ton AT; McKinney Y; Weaver J; Eclarinal P; Forest A; Afari G; Bhattacharyya S; Mease RC; Merino MJ; Pinto P; Wood BJ; Jacobs P; Pomper MG; Choyke PL; Turkbey B
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):4-11. PubMed ID: 28894899
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Wondergem M; van der Zant FM; Broos WAM; Roeleveld TA; Donker R; Ten Oever D; Geenen RWF; Knol RJJ
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):521-531. PubMed ID: 32719916
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Eiber M; Kroenke M; Wurzer A; Ulbrich L; Jooß L; Maurer T; Horn T; Schiller K; Langbein T; Buschner G; Wester HJ; Weber W
    J Nucl Med; 2020 May; 61(5):696-701. PubMed ID: 31836682
    [No Abstract]   [Full Text] [Related]  

  • 35.
    Solanki AA; Savir-Baruch B; Liauw SL; Michalski J; Tward JD; Vapiwala N; Teoh EJ;
    Pract Radiat Oncol; 2020; 10(5):354-362. PubMed ID: 32464368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial multicentre experience of
    Siriwardana A; Thompson J; van Leeuwen PJ; Doig S; Kalsbeek A; Emmett L; Delprado W; Wong D; Samaratunga H; Haynes AM; Coughlin G; Stricker P
    BJU Int; 2017 Nov; 120(5):673-681. PubMed ID: 28548372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gallium-68-prostate-specific membrane antigen (
    van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of
    Chevalme YM; Boudali L; Gauthé M; Rousseau C; Skanjeti A; Merlin C; Robin P; Giraudet AL; Janier M; Talbot JN
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2935-2950. PubMed ID: 33416958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High detection rate in [
    Watabe T; Uemura M; Soeda F; Naka S; Ujike T; Hatano K; Sasaki H; Kamiya T; Shimosegawa E; Kato H; Cardinale J; Tateishi U; Nonomura N; Giesel FL
    Ann Nucl Med; 2021 Apr; 35(4):523-528. PubMed ID: 33661475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [
    Vogel MME; Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Mix M; la Fougère C; Eiber M; Christiansen H; Belka C; Grosu AL; Müller AC; Guckenberger M; Combs SE
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2328-2338. PubMed ID: 32179961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.